MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the JMP Securities Healthcare Focus Conference in New York City.
The VIVUS presentation will take place at the New York Palace Hotel on Monday, October 5, 2009 at 4:00 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/jmp9/vvus/ or http://www.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
SOURCE VIVUS, Inc.
CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,
+1-650-934-5200; or Investor Relations, Brian Korb of The Trout Group,
+1-646-378-2923; or Media Relations, Sheryl Seapy of Pure Communications,
Inc., +1-949-608-0841, both for VIVUS, Inc.
Web site: http://www.vivus.com/
